Anti-Influenza Class 1 New Drug ADC189 Approved Clinically in China

Text|Pharmaceutical Mission Hills

Recently, Antikang Biotechnology announced that the company's independent research and development of the company's independent research and development of the new drug ADC189 for the treatment and prevention of influenza A and B has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

Screenshot source: CDE official website

It is reported that ADC189 has a new anti-influenza mechanism that can directly inhibit virus replication

Antikang Bio's design and development of ADC189 aims to combat influenza A and B viruses, including influenza strains resistant to oseltamivir and avian influenza strains (H7N9, H5N1)

It is worth mentioning that a single oral dose of this new drug under development can block influenza virus replication within 24 hours

Public information shows that the Antikang bioscientist team has long focused on the research and development of small molecule innovative drugs in the field of anti-infection

According to Dr.

Reference materials:

[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.